4.7 Article

Studies on gambogic acid (IV): Exploring structure-activity relationship with IκB kinase-beta (IKKβ)

Journal

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 51, Issue -, Pages 110-123

Publisher

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2012.02.029

Keywords

IKK beta; NF-kappa B signaling pathway; Caged xanthone; Pharmacophoric motif; Inhibitor

Funding

  1. State Key Laboratory of Natural Medicines, China Pharmaceutical University [JKGQ201103]
  2. National Major Science and Technology Project of China (Innovation and Development of New Drugs) [2008ZX09401-001, 2009ZX09501-003]
  3. National Natural Science Foundation of China [90713038]

Ask authors/readers for more resources

Previously we have reported a series of gambogic acid's analogs and have identified a compound that possessed comparable in vitro growth inhibitory effect as gambogic acid. However, their target protein as well as the key pharmacophoric motifs on the target have not been identified yet. Herein we report that gambogic acid and its analogs inhibit the activity of I kappa B Kinase-beta (IKK beta) through suppressing the activation of TNF alpha/NF-kappa B pathway, which in turn induces A549 and U251 cell apoptosis. IKK beta can serve as one of gambogic acid's targets. The preparation of the compounds was carefully discussed in the article. Caged 4-oxa-tricyclo[4.3.1.0(3,7)]dec-2-one xanthone, which was identified as the pharmacophoric scaffold, represents a promising therapeutic agent for cancer and useful probe against NF-kappa B pathway. (C) 2012 Elsevier Masson SAS. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available